Our recent agreements


Global development and commercialization rights of elacestrant, an oral SERD currently being evaluated in the EMERALD Phase 3 study as hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer. Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.


Menarini strengthened its respiratory value proposition with various commercial deals in Asthma and COPD for GSK’s Ellipta’s Portfolio (LABA, LAMA, LAMA/LABA). In addition, Nucala® (mepolizumab) is also included for severe Asthma


Melinta and Menarini have entered into a commercial and co-development agreement for Quofenix®, Vaborem™, Orbactiv® and Minocin® in 68 countries, thus building a high value antinfectives platform.